Skip to main content
SpringerLink
Log in

Atrial fibrillation and stroke prevention: is warfarin still an option? Yes

Debate at the Controversies in Neurology congress, Beijing October 2011

  • Neurology and Preclinical Neurological Studies - CONy Pro/Con debate
  • Published:
Journal of Neural Transmission Aims and scope Submit manuscript

Abstract

With the advent of new oral anticoagulants, the place of warfarin for stroke prevention in patients with atrial fibrillation needs re-evaluation. Warfarin is difficult to use, because of large individual differences in response and metabolism, many significant interactions with drugs and foods, and fluctuations in vitamin K absorption. It requires frequent blood testing and dose adjustments, so with good reason patients and physicians are eager for the newer agents that are easier to use. However, the purchase price of the new anticoagulants is so high that warfarin will remain in widespread use. It is important therefore for physicians to know how to use it well. Anticoagulants work much better for stroke prevention in atrial fibrillation than do antiplatelet agents; physicians need to understand the concept of red thrombus (for which anticoagulants are required) versus white thrombus—platelet aggregates—which are the target of antiplatelet agents. Stroke from atrial fibrillation increases steeply with age, and the elderly benefit disproportionately from anticoagulation. It is still necessary for physicians to know how to use warfarin, and to use it better than it has been used in the past.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  • Boston Collaborative Drug Surveillance Program (1972) Interaction between chloral hydrate and warfarin. A report from the Boston Collaborative Drug Surveillance Program, Boston Universtiy Medical Center. N Engl J Med 286:53–55. doi:10.1056/NEJM197201132860201

    Google Scholar 

  • Bang H, Mazumdar M, Spence JD (2006) Tutorial in biostatistics: analyzing associations between total plasma homocysteine and B vitamins using optimal categorization and segmented regression. Neuroepidemiology 27:188–200

    Article  PubMed  Google Scholar 

  • Caplan LR, Fisher M (2007) The endothelium, platelets, and brain ischemia. Rev Neurol Dis 4:113–121

    PubMed  Google Scholar 

  • Connolly SJ, Eikelboom JW, Ng J, Hirsh J, Yusuf S, Pogue J, de Caterina R, Hohnloser S, Hart RG (2011) Net Clinical Benefit of Adding Clopidogrel to Aspirin Therapy in Patients With Atrial Fibrillation for Whom Vitamin K Antagonists Are Unsuitable. Ann Intern Med 155:579–586. doi:10.1059/0003-4819-155-9-201111010-00004

    Article  PubMed  Google Scholar 

  • del Zoppo GJ, Eliasziw M (2011) New options in anticoagulation for atrial fibrillation. N Engl J Med 365:952–953. doi:10.1056/NEJMe1107516

    Article  PubMed  Google Scholar 

  • Deykin D (1967) Thrombogenesis. N Engl J Med 276:622–628

    Article  PubMed  CAS  Google Scholar 

  • Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M (2011) Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124:1573–1579. doi:10.1161/CIRCULATIONAHA.111.029017

    Article  PubMed  CAS  Google Scholar 

  • Fisher CM (1959) Observations of the fundus oculi in transient monocular blindness. Neurology 9:333–347

    Article  PubMed  CAS  Google Scholar 

  • Gladstone DJ, Bui E, Fang J, Laupacis A, Lindsay MP, Tu JV, Silver FL, Kapral MK (2009) Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke 40:235–240

    Article  PubMed  CAS  Google Scholar 

  • Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS (2005) Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 165:1095–1106. doi:10.1001/archinte.165.10.1095

    Article  PubMed  CAS  Google Scholar 

  • House AA, Eliasziw M, Cattran DC, Churchill DN, Oliver MJ, Fine A, Dresser GK, Spence JD (2010) Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA 303:1603–1609. doi:10.1001/jama.2010.490

    Article  PubMed  CAS  Google Scholar 

  • Hylek EM, Frison L, Henault LE, Cupples A (2008) Disparate stroke rates on warfarin among contemporaneous cohorts with atrial fibrillation: potential insights into risk from a comparative analysis of SPORTIF III versus SPORTIF V. Stroke 39:3009–3014

    Article  PubMed  CAS  Google Scholar 

  • Juurlink DN (2007) Drug interactions with warfarin: what clinicians need to know. CMAJ 177:369–371

    PubMed  Google Scholar 

  • Man-Son-Hing M, Nichol G, Lau A, Laupacis A (1999) Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med 159:677–685

    Article  PubMed  CAS  Google Scholar 

  • Poli D, Antonucci E, Cecchi E, Marcucci R, Liotta AA, Cellai AP, Lenti M, Gensini GF, Abbate R, Prisco D (2005) Culprit factors for the failure of well-conducted warfarin therapy to prevent ischemic events in patients with atrial fibrillation: the role of homocysteine. Stroke 36:2159–2163

    Article  PubMed  CAS  Google Scholar 

  • Rombouts EK, Rosendaal FR, Van Der Meer FJ (2007a) Daily vitamin K supplementation improves anticoagulant stability. J Thromb Haemost 5:2043–2048

    Article  PubMed  CAS  Google Scholar 

  • Rombouts EK, Rosendaal FR, van der Meer FJ (2007b) Daily vitamin K supplementation improves anticoagulant stability. J Thromb Haemost 5:2043–2048

    Article  PubMed  CAS  Google Scholar 

  • Samsa GP, Matchar DB, Goldstein LB, Bonito AJ, Lux LJ, Witter DM, Bian J (2000) Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. Arch Intern Med 160:967–973

    Article  PubMed  CAS  Google Scholar 

  • Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A, Kim RB, Roden DM, Stein CM (2008) Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 358:999–1008

    Article  PubMed  CAS  Google Scholar 

  • Sellers EM, Koch-Weser J (1970) Potentiation of warfarin-induced hypoprothrombinemia by chloral hydrate. N Engl J Med 283:827–831. doi:10.1056/NEJM197010152831601

    Article  PubMed  CAS  Google Scholar 

  • Sellers EM, Koch-Weser J (1971) Kinetics and clinical importance of displacement of warfarin from albumin by acidic drugs. Ann N Y Acad Sci 179:213–225

    Article  PubMed  CAS  Google Scholar 

  • Spence JD (2006) Nutrition and stroke prevention. Stroke 37:2430–2435

    Article  PubMed  Google Scholar 

  • Spence JD (2007) Homocysteine-lowering therapy: a role in stroke prevention? Lancet Neurol 7:830–838

    Article  Google Scholar 

  • Spence D (2009a) Mechanisms of thrombogenesis in atrial fibrillation. Lancet 373:1006–1007

    Article  PubMed  Google Scholar 

  • Spence JD (2009b) Stroke: atrial fibrillation, stroke prevention therapy and aging. Nat Rev Cardiol 6:448–450

    Article  PubMed  CAS  Google Scholar 

  • Spence JD, Stampfer MJ (2011) Understanding the complexity of homocysteine lowering with vitamins: the potential role of subgroup analyses. JAMA 306(23):2610–2611

    Google Scholar 

  • Spence JD, Bang H, Chambless LE, Stampfer MJ (2005) Vitamin intervention for stroke prevention trial: an efficacy analysis. Stroke 36:2404–2409

    Article  PubMed  CAS  Google Scholar 

  • van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A (2010) Dabigatran etexilate–a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103:1116–1127. doi:10.1160/TH09-11-0758

    Article  PubMed  Google Scholar 

  • van Walraven C, Hart RG, Connolly S, Austin PC, Mant J, Hobbs FD, Koudstaal PJ, Petersen P, Perez-Gomez F, Knottnerus JA, Boode B, Ezekowitz MD, Singer DE (2009) Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke 40:1410–1416. doi:10.1161/STROKEAHA.108.526988

    Article  PubMed  Google Scholar 

  • Vogiatzoglou A, Oulhaj A, Smith AD, Nurk E, Drevon CA, Ueland PM, Vollset SE, Tell GS, Refsum H (2009) Determinants of plasma methylmalonic acid in a large population: implications for assessment of vitamin B12 status. Clin Chem 55:2198–2206

    Article  PubMed  CAS  Google Scholar 

  • Wolf PA, Abbott RD, Kannel WB (1991) Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22:983–988

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Stroke Prevention and Atherosclerosis Research Centre, Robarts Research Institute, University of Western Ontario, 1400 Western Road, London, ON, N6G 2V2, Canada

    J. David Spence

Authors
  1. J. David Spence
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. David Spence.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Spence, J.D. Atrial fibrillation and stroke prevention: is warfarin still an option? Yes. J Neural Transm 120, 1447–1451 (2013). https://doi.org/10.1007/s00702-012-0941-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00702-012-0941-5

Keywords

Search

Navigation